Empagliflozin as adjunct to insulin in patients with type 1 diabetes: a 4‐week, randomized, placebo‐controlled trial (EASE‐1)

AIMS: To investigate the pharmacodynamics, efficacy and safety of empagliflozin as adjunct to insulin in patients with type 1 diabetes. METHODS: A total of 75 patients with glycated haemoglobin (HbA1c) concentrations of ≥7.5 to ≤10.5% (≥58 to ≤91 mmol/mol) were randomized to receive once‐daily empag...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Diabetes Obes Metab
Autori principali: Pieber, T. R., Famulla, S., Eilbracht, J., Cescutti, J., Soleymanlou, N., Johansen, O. E., Woerle, H. J., Broedl, U. C., Kaspers, S.
Natura: Artigo
Lingua:Inglês
Pubblicazione: Blackwell Publishing Ltd 2015
Soggetti:
Original Articles
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4745028/
https://ncbi.nlm.nih.gov/pubmed/26080652
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/dom.12494
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi